Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia

Abstract

The biological and clinical features of chronic lymphocytic leukemia (CLL) exhibited profound heterogeneity across Chinese and patients of predominately European descent. However, the age-related peculiarities and risk assessment of Chinese CLL patients remained ill-defined. The present study demonstrated that CLL patients were characterized by the earlier age at onset in China (median age at diagnosis: 63 years old) than in the United States (median age at diagnosis: 69 years old). Young patients from Shandong Provincial Hospital CLL database displayed prolonged overall survival than the Surveillance, Epidemiology, and End Results cohort. Furthermore, among Chinese CLL patients, young patients showed an increased relapse rate compared with elderly patients. To optimize the risk assessment of CLL patients, novel risk score models named PR-Score and HBG-Score were developed for predicting the outcomes of young and elderly CLL patients respectively. The neonatal survival prediction systems were superior to international prognostic index for CLL (CLL-IPI) and Binet stage in assessing the overall survival and progression free survival of CLL patients. The analyses highlighted refinement of risk evaluation for CLL patients in different age groups, providing insights into individualized diagnosis and treatment of CLL.

Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model

“…CLL presents a variable disease course and typically involves chromosomal deletions [28,29]. The age of onset, genetic profile and other characteristics between different races are heterogenous [30]. Due to the RNA sequencing technology, a plethora of ncRNAs have been explored and confirmed to exert pivotal roles in different physiopathological processes of cells [31,32].…”

MYD88-Mutated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma as a Distinctive Molecular Subgroup Is Associated with Atypical Immunophenotypes in Chinese Patients

“…CLL/SLL is a hematologic neoplasm that is heterogeneous in populations from different backgrounds in the West and Asia, particularly in individuals from China [ 5 , 6 , 7 , 8 , 9 ]. Notably, several apparent differences between Chinese CLL/SLL patients and those from Western countries have been reported, such as age distribution, chromosomal aberrations, gene variants, IGHV family usage, and treatment outcomes [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ], and additional findings need further investigation. While studies including large cohorts of Chinese patients or population-based studies in mainland China with CLL/SLL are rare, an understanding of the features of CLL/SLL in Chinese patients will help guide future research on disease aetiology, pathogenesis, biology, and advanced clinical application.…”